European Medicines Agency
Evaluation of Medicines for Human Use

Doc Ref : EMEA/477562/2008

CHMP ASSESSMENT REPORT
FOR

Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals

Common Name:
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/VietNam/1194/2004 NIBRG-14

Procedure No. EMEA/H/C/001015

Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted.

7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

TABLE OF CONTENTS

1. BACKGROUND INFORMATION ON THE PROCEDURE

1.1 Submission of the dossier

The applicant GlaxoSmithKline Biologicals S.A. submitted on 5 May 2008 an application for Marketing Authorisation to the European Medicines Agency (EMEA) for *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals*, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004 .

The legal basis for this application refers to Article 10(c) of Directive 2001/83/EC, as amended – relating to informed consent from the marketing authorisation holder, for the authorised medicinal product: Prepandrix (EU/1/08/453/001)

The application submitted is a complete dossier composed of administrative information, quality, non-clinical and clinical data with a letter from a MAH GlaxoSmithKline Biologicals S.A. allowing the cross reference to relevant quality, non-clinical and/or clinical data

The applicant applied for the following indication: Active immunisation against H5N1 subtype of Influenza A virus.

Licensing status:
The initial product, Prepandrix, was given a Community Marketing Authorisation on 14 May 2008

The Rapporteur and Co-Rapporteur appointed by the CHMP were:
Rapporteur: **Dr Ian Hudson** Co-Rapporteur: **Barbara van Zwieten-Boot**

1.2 Steps taken for the assessment of the product

- The application was received by the EMEA on 5 May 2008.
- The procedure started on 28 May 2008.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 27 June 2008. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 30 June 2008.
- During the meeting on 21-24 July 2008, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* on 24 July 2008.
- The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 16 July 2008.

2 SCIENTIFIC DISCUSSION

2.1 Introduction

An influenza pandemic is a global outbreak of influenza disease that occurs when a type A influenza strain to which most or all humans are immunologically naïve emerges to cause clinically apparent illness, and then spreads easily from person to person worldwide. Pandemics are different from seasonal outbreaks of influenza, as the latter are caused by subtypes of influenza viruses that are already circulating in the world whereas pandemics are caused by new subtypes or by subtypes that have not circulated among people for a long time.

The marketing authorisation application for *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* was submitted as an informed consent application in accordance with Article 10c of Directive 2001/83/EC, as amended.

Therefore, consent from the MAH of the Prepandrix application, which had been submitted as a full application under Art 8(3) of Directive 2001/83/EC as amended, has been given allowing access to Module 2 to Module 5 of the initial dossier of this authorised product and any subsequent post-marketing procedures submitted, assessed and approved.

As a consequence, quality, safety and efficacy of the *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* is identical to the quality, safety and efficacy profile of Prepandrix[1]. Information on the scientific discussions can be found in the Prepandrix CHMP assessment report and in the European Public Assessment Report (EPAR).

Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals is a split virion inactivated influenza vaccine. The final formulation contains 3.75 µg haemagglutinin (HA) of A/VietNam/1194/2004 NIBRG-14 (H5N1) per 0.5 ml dose adjuvanted by ASO3.

Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals is indicated for active immunisation against H5N1 subtype of Influenza A virus.
This indication is based on immunogenicity data from healthy subjects aged 18-60 years following administration of two doses of vaccine prepared from A/VietNam/1194/2004 NIBRG-14 (H5N1).
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals should be used in accordance with official guidance.

It is intended for use in adults from the age of 18 years onwards and from WHO Pandemic phase 3 onwards.

2.2 Quality aspects

Since this application is an informed consent of the Prepandrix application, the quality data in support of the *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* application are identical to the quality data of the Prepandrix dossier which have been assessed and approved (including all post-marketing procedures).

[1] The original application for Prepandrix was filed in accordance with the *Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context* (CHMP/VWP/263499/2006). This guideline was developed to cover the possibility that influenza vaccines containing or derived from strains with a pandemic potential (such as H5N1 avian influenza strains) might be used from WHO Phase 3 onwards in an attempt to provide some protection against clinically apparent disease when an actual pandemic commenced.

2.3 Non-clinical aspects

Since this application is an informed consent of the Prepandrix application, the non-clinical data in support of the *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* application are identical to the non-clinical data of the Prepandrix dossier which have been assessed and approved (including all post-marketing procedures).

2.4 Clinical aspects

Since this application is an informed consent of the Prepandrix application, the clinical data in support of the *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* application are identical to the clinical data of the Prepandrix dossier which have been assessed and approved (including all post-marketing procedures).

2.5 Pharmacovigilance

Detailed description of the Pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the applicant, which is identical to that of the authorised product Prepandrix, fulfilled the legislative requirements.

Risk Management Plan

The risk management plan, which is identical to that of the authorised product Prepandrix, was drafted in accordance with the CHMP core RMP for vaccines intended for use from WHO Phase 3 onwards. The applicant committed to update the RMP for the current application in line with the outcome of the assessment of the RMP submitted on 29 April 2008 for Prepandrix.

2.6 Overall conclusions, risk/benefit assessment and recommendation

- User consultation

The applicant has committed to perform a further round of user testing with the final approved PL in the post-authorisation period.

- Risk-benefit assessment

Since this application is an informed consent of the Prepandrix application, the risk-benefit assessment of the *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* application is identical to the risk-benefit assessment of the Prepandrix dossier which have been assessed and approved.

Conclusions

The overall B/R of Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals is positive.

A risk management plan was submitted in accordance with the CHMP-recommended core RMP for these types of vaccines when intended for use in the pre-pandemic period.

Recommendation

Since this application is an informed consent of the Prepandrix application, the CHMP considered by consensus that the risk-benefit balance of *Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals* for the active immunisation against H5N1 subtype of Influenza A virus was favourable and therefore recommended the granting of the marketing authorisation.